AIM (AIM ImmunoTech) רווח נקי למניה (EPS TTM)

AIM ImmunoTech's critical dependence on a single drug creates binary risks, as confirmed by the YoY EPS change on a rolling 12-month basis on GURU.Markets, where 84.20 reflects the metric's baseline. Brand stability is supported by the trust of patients with chronic fatigue syndrome, while strategic alliances with oncology centers develop Ampligen, enhancing M&A potential within the sector.

This indicator measures the annual growth rate of net income per share over a twelve-month period. An increase in this metric signals the business's ability to generate added value amid tight monetary policy. By analyzing the annual TTM net income per share dynamics, an investor determines the degree of the asset's undervaluation. For AIM ImmunoTech (AIM), this metric is critical due to the polarization of opinions regarding the company, as it allows for a comparison of financial results with the professional confidence physicians place in the potential of Ampligen.